Materialise (MTLS) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
2 Feb, 2026Executive summary
Achieved record Q2 2024 revenue of €68.8 million, up 6.2% year-over-year, with growth in all business segments.
Net profit reached €3.9 million, or €0.07 per diluted share, reversing a net loss in Q2 2023.
Adjusted EBIT improved to €3.9 million (5.6% margin), and adjusted EBITDA rose to €9.2 million.
Net cash position increased to €67.5 million, up €4.3 million since year-end 2023.
Strategic milestones included the acquisition of FEops and a partnership with nTop to enhance 3D printing and medical capabilities.
Financial highlights
Gross profit margin was 57.0%, stable year-over-year, with gross profit at €39.2 million.
Adjusted EBIT improved to €3.9 million from a loss last year; adjusted EBITDA rose to €9.2 million from €4.8 million.
Cash and equivalents stood at €125.5 million, with borrowings reduced to €58.0 million.
Operating cash flow for Q2 2024 was €8.4 million; capital expenditures totaled €8.5 million.
Net shareholders' equity increased to €243.1 million from €236.6 million at December 31, 2023.
Outlook and guidance
Full-year 2024 revenue expected in the €265–275 million range.
Adjusted EBIT guidance maintained at €11–14 million, despite integration costs from the FEops acquisition.
Latest events from Materialise
- Medical segment drove 4.3% revenue growth, but profits fell; 2025 guidance unchanged.MTLS
Q1 202517 Mar 2026 - Q4 revenue up 6.8%, Medical segment leads, 2026 EBIT guided at EUR 10–12 million.MTLS
Q4 202519 Feb 2026 - Q3 2024 revenue up 14.2% to €68.7M, led by Medical; full-year outlook reaffirmed.MTLS
Q3 202418 Jan 2026 - Medical growth drove profit gains, but Manufacturing and Software faced headwinds in 2024.MTLS
Q4 202423 Dec 2025 - Medical segment growth offsets overall revenue decline; cost control sustains profitability.MTLS
Q2 202516 Nov 2025 - Q3 2025 revenue fell 3.5% as Medical growth offset declines in Manufacturing and Software.MTLS
Q3 202529 Oct 2025 - 2024 revenue rose 4.2% to 266.8 mEUR, with Medical segment leading growth.MTLS
Corporate Presentation6 Jun 2025